This webinar provided an overview of animal infection models commonly used for studies of antibiotics against gram-negative bacteria. The webinar was driven by the COMBINE objective to harmonse and standardise […]
December 3, 2020, 3.30PM-4.30PM CET Peter Warn is an experienced antimicrobial discovery scientist and consultant with a long and successful record of working in the anti-infective discovery industry. His expertise […]
The webinar covered processes for working with aggregated clinical data in the COMBINE consortium and AMR Accelerator. Firstly, the team outlined a set of procedures established for assessing the ethical […]
This workshop provided an open discussion forum to identify, propose and prioritise specific challenges, success and risk factors in the development of vaccines against nosocomial AMR pathogens. Participants included experts […]
Each year, World Tuberculosis (TB) Day is commemorated on March 24 to raise public awareness about the devastating health, social and economic consequences of TB, and to step up efforts […]
Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, this conference will discuss data-driven and solution-based approaches that focus on developing high value clinical candidates, […]
As AMR emerges, new strategies for the treatment of infection and identification of resistant microbes are crucial. This JPIAMR activity, led by the UK Medical Research Council (MRC) with support […]
The COMBINE project is part of the IMI AMR Accelerator. One of the scientific aims of COMBINE is to improve and standardize the pneumonia animal model used in AMR research […]
This live webinar will discuss the following topics: Are CMC and formulation efforts treated as the foster child in the innovation and development armament? Underestimating CMC and formulation aspects can […]
This webinar provided a unique opportunity for the antibiotic community. The Innovative Medicines Initiative's GNA NOW Consortium was looking for a novel antibiotic compound to progress to a clinical candidate […]
